Oncology R&D: the patient insights we’re still missing, and how to catch upImagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and Share XOncology R&D: the patient insights we’re still missing, and how to catch uphttps://deep-dive.pharmaphorum.com/magazine/oncology-2021/oncology-rd-patient-engagement/
Almirall kicks off another hunt for skin disease therapy partnershipsSpanish drugmaker Almirall has launched another search for early-stage research projects that it can partner in dermatology, its Share XAlmirall kicks off another hunt for skin disease therapy partnershipshttps://pharmaphorum.com/news/almirall-kicks-off-another-hunt-for-skin-disease-therapy-partnerships/
Sanofi doubles down on mRNA jabs with €400m-a-year R&D driveSanofi has just significantly increased its investment in mRNA vaccine development, earmarking €400 million ($475 million) a year Share XSanofi doubles down on mRNA jabs with €400m-a-year R&D drivehttps://pharmaphorum.com/news/sanofi-doubles-down-on-mrna-jabs-with-e400m-yearly-rd-drive/
Kintor hits back at press criticism of COVID drug with US trial updateThe China-based biotech Kintor has hit back at press criticism of its potential COVID drug proxalutamide, releasing further Share XKintor hits back at press criticism of COVID drug with US trial updatehttps://pharmaphorum.com/news/kintor-hits-back-at-press-criticism-of-covid-drug-with-us-trial-update/
BMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drugBristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to Share XBMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drughttps://pharmaphorum.com/news/bms-agrees-deal-worth-up-to-1-56bn-for-agenus-tigit-cancer-drug/
Elliott Management could force out GSK CEO Walmsley, investor warnsSpeculation is mounting GlaxoSmithKline’s CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the Share XElliott Management could force out GSK CEO Walmsley, investor warnshttps://pharmaphorum.com/news/elliott-management-could-force-out-gsk-ceo-walmsley-investor-warns/
Novo Nordisk moves chronic kidney disease drug ziltivekimab into phase 3Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic Share XNovo Nordisk moves chronic kidney disease drug ziltivekimab into phase 3https://pharmaphorum.com/news/novo-nordisk-moves-chronic-kidney-disease-drug-ziltivekimab-into-phase-3/
Scepticism in press over Kintor’s COVID-19 US drug trialChina’s Kintor Pharmaceutical has begun late-stage US clinical development of its potential COVID drug proxalutamide – but there Share XScepticism in press over Kintor’s COVID-19 US drug trialhttps://pharmaphorum.com/news/doubts-emerge-over-kintors-covid-19-us-drug-trial/
Novavax delays COVID vaccine filings until Q3Novavax has finally provided some clarity about when its long-awaited COVID-19 vaccine will be ready, saying regulatory filings Share XNovavax delays COVID vaccine filings until Q3https://pharmaphorum.com/news/novavax-delays-covid-vaccine-filings-until-q3-blaming-lack-of-manufacturing-data/
